Breast cancer risk reduction: Notable achievements and remaining challenges
Author:
Affiliation:
1. Breast Medical Oncology/Research Geisinger Health System Danville Pennsylvania
Publisher
Hindawi Limited
Subject
Oncology,Surgery,Internal Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.13717
Reference49 articles.
1. Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention
2. Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models
3. Projecting Individualized Probabilities of Developing Breast Cancer for White Females Who Are Being Examined Annually
4. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction
5. Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Computer-aided drug designing illuminate polypharmacology of natural products against multiple estrogen receptor;Computational Approaches in Drug Discovery, Development and Systems Pharmacology;2023
2. Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial;Cancer Prevention Research;2022-06-09
3. Development of an electrochemical sensor based on (rGO-CNT) nanocomposite for raloxifene analysis;Materials Chemistry and Physics;2021-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3